13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
142 檔
27.1%
According to the latest 13F quarterly dataset, Bellevue Group AG managed an equity portfolio of $4.8B at the end of Q2 2025, spanning 142 distinct U.S. exchange-listed positions.
In Q2 2025, Bellevue Group AG adopted a defensive or profit-taking posture, trimming 61 positions and completely liquidating 13 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 6.94% | +0.44% | -1.35% | |
| 2 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 6.84% | -1.63% | — | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 5.04% | +0.08% | — | |
| 4 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 4.86% | -1.84% | -11.95% | |
| 5 | ABT | Abbott Laboratories | Stock-Healthcare | 4.69% | -1.00% | +0.51% | |
| 6 | SYK | Stryker CORP | Stock-Healthcare | 4.67% | +0.08% | -5.56% | |
| 7 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.54% | -1.01% | -11.04% | |
| 8 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.33% | -1.20% | +6.91% | |
| 9 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.18% | -1.39% | -9.52% | |
| 10 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.71% | +0.56% | +4.69% | |
| 11 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.63% | — | +2.13% | |
| 12 | INCY | Incyte CORP | Stock-Healthcare | 2.36% | — | -24.93% | |
| 13 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.33% | — | +58.74% | |
| 14 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.30% | -1.36% | +17.57% | |
| 15 | MDT | Medtronic plc | Stock-Healthcare | 1.77% | -0.33% | -1.84% | |
| 16 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.69% | -0.15% | +99.86% | |
| 17 | DXCM | Dexcom Inc | Stock-Healthcare | 1.66% | -0.01% | -19.10% | |
| 18 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.53% | -0.19% | -8.53% | |
| 19 | PODD | Insulet CORP | Stock-Healthcare | 1.52% | -0.41% | -19.27% | |
| 20 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.48% | +0.03% | +7.68% | |
| 21 | BDX | Becton Dickinson And Co | Stock-Healthcare | 1.20% | -0.11% | -8.01% | |
| 22 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.08% | — | +20.59% | |
| 23 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.01% | +0.09% | +76.77% | |
| 24 | PEN | Penumbra Inc | Stock-Healthcare | 0.98% | -0.10% | EXIT | |
| 25 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.98% | +0.35% | -13.62% | |
| 26 | RMD | Resmed Inc | Stock-Healthcare | 0.94% | -0.24% | — | |
| 27 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 0.90% | -0.51% | -0.45% | |
| 28 | BHVN | Biohaven Ltd. | Stock-Other | 0.87% | — | +37.34% | |
| 29 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.84% | -0.37% | -1.71% | |
| 30 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.84% | -0.24% | +60.37% | |
| 31 | CI | THE Cigna Group | Stock-Healthcare | 0.81% | -0.23% | -5.81% | |
| 32 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.80% | — | — | |
| 33 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.80% | -1.15% | EXIT | |
| 34 | MRNA | Moderna Inc | Stock-Healthcare | 0.75% | — | -18.41% | |
| 35 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 0.72% | -0.02% | +0.07% | |
| 36 | ELV | Elevance Health Inc | Stock-Healthcare | 0.70% | +0.09% | +104.84% | |
| 37 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.70% | +0.01% | -6.25% | |
| 38 | MCK | Mckesson CORP | Stock-Healthcare | 0.65% | -0.31% | +32.33% | |
| 39 | ABBV | Abbvie Inc | Stock-Healthcare | 0.65% | -0.27% | +18.06% | |
| 40 | ALGN | Align Technology Inc | Stock-Healthcare | 0.63% | -0.07% | -0.14% | |
| 41 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.63% | +0.59% | +11.57% | |
| 42 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.62% | -0.06% | +17.92% | |
| 43 | DHR | Danaher CORP | Stock-Healthcare | 0.60% | -0.33% | +10.05% | |
| 44 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.59% | — | EXIT | |
| 45 | STE | STERIS plc | Stock-Healthcare | 0.58% | -0.09% | — | |
| 46 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.56% | -0.16% | -0.27% | |
| 47 | NTRA | Natera Inc | Stock-Healthcare | 0.55% | -0.01% | +30.27% | |
| 48 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.54% | -0.10% | -8.11% | |
| 49 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.49% | +0.13% | NEW | |
| 50 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.43% | -0.27% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | +1.5% | — | Unchanged |
| 2 | AKRO | Akero Therapeutics Inc | +1.2% | +58.74% | Add |
| 3 | IMCR | Immunocore Holdings Plc-adr | +0.9% | +99.86% | Add |
| 4 | 2655787D | Blueprint Medicines CORP | +0.8% | NEW | New buy |
| 5 | NBIX | Neurocrine Biosciences Inc | +0.5% | — | Unchanged |
| 6 | SRRK | Scholar Rock Holding CORP | +0.5% | +17.57% | Add |
| 7 | HCA | Hca Healthcare Inc | +0.4% | +60.37% | Add |
| 8 | AGIO | Agios Pharmaceuticals Inc | +0.3% | +2.13% | Add |
| 9 | ELV | Elevance Health Inc | +0.3% | +104.84% | Add |
| 10 | TMO | Thermo Fisher Scientific Inc | +0.3% | +76.77% | Add |
| 11 | RVMD | Revolution Medicines Inc | +0.2% | +4.69% | Add |
| 12 | CLDX | Celldex Therapeutics Inc | +0.2% | +7.68% | Add |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | +0.2% | -11.95% | Trim |
| 14 | RLAY | Relay Therapeutics Inc | +0.2% | +11.57% | Add |
| 15 | MCK | Mckesson CORP | +0.2% | +32.33% | Add |
| 16 | NTRA | Natera Inc | +0.2% | +30.27% | Add |
| 17 | DGX | Quest Diagnostics Inc | +0.2% | NEW | New buy |
| 18 | IDXX | Idexx Laboratories Inc | +0.2% | -0.45% | Trim |
| 19 | TEVA | Teva Pharmaceutical-sp Adr | +0.2% | +1356.97% | Add |
| 20 | VEEV | Veeva Systems Inc-class A | +0.1% | +0.07% | Add |
| 21 | TMDX | Transmedics Group Inc | +0.1% | -24.86% | Trim |
| 22 | RMD | Resmed Inc | +0.1% | — | Unchanged |
| 23 | EWTX | Edgewise Therapeutics Inc | +0.1% | +94.27% | Add |
| 24 | ASND | Ascendis Pharma A/S | +0.1% | +1408.16% | Add |
| 25 | OMDA | Omada Health Inc | +0.1% | NEW | New buy |
| 26 | ALGN | Align Technology Inc | +0.1% | -0.14% | Trim |
| 27 | HUM | Humana Inc | +0.1% | +73.60% | Add |
| 28 | PRCT | Procept Biorobotics CORP | +0.1% | +17.92% | Add |
| 29 | MASI* | Masimo CORP | +0.1% | +28.46% | Add |
| 30 | GPCR | Structure Therapeutics Inc | +0.1% | +57.20% | Add |
| 31 | ABT | Abbott Laboratories | +0.1% | +0.51% | Add |
| 32 | LH | Labcorp Holdings Inc | +0.1% | +30.39% | Add |
| 33 | BNTX | Biontech Se-adr | +0.1% | +339.97% | Add |
| 34 | BDTX | Black Diamond Therapeutics I | +0.1% | — | Unchanged |
| 35 | ANNX | Annexon Inc | +0.1% | — | Unchanged |
| 36 | CNC | Centene CORP | +0.1% | +61.58% | Add |
| 37 | DXCM | Dexcom Inc | 0% | -19.10% | Trim |
| 38 | BEAM | Beam Therapeutics Inc | 0% | +20.59% | Add |
| 39 | TXG | 10x Genomics Inc-class A | 0% | +41.45% | Add |
| 40 | DHR | Danaher CORP | 0% | +10.05% | Add |
| 41 | STE | STERIS plc | 0% | — | Unchanged |
| 42 | ABBV | Abbvie Inc | 0% | +18.06% | Add |
| 43 | HO1 | Hologic Inc | 0% | — | Unchanged |
| 44 | WAY | Waystar Holding CORP | 0% | +4.28% | Add |
| 45 | CAH | Cardinal Health Inc | 0% | -3.68% | Trim |
| 46 | RYTM | Rhythm Pharmaceuticals Inc | 0% | +34.44% | Add |
| 47 | NVO | Novo-nordisk A/s-spons Adr | 0% | NEW | New buy |
| 48 | ILMN | Illumina Inc | 0% | — | Unchanged |
| 49 | PLNT | Planet Fitness Inc - Cl A | 0% | NEW | New buy |
| 50 | GKOS | Glaukos CORP | 0% | — | Unchanged |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 142 disclosed positions in Q2 2025.
During Q2 2025, Bellevue Group AG's top holdings by market value included ARGX (6.9%)、IONS (6.8%)、NBIX (5.0%). The largest single position, ARGX, represented 6.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, IONS, NBIX) accounted for 27.1% of total reported equity market value during Q2 2025.
Top New Position Initiated
2655787D
市值: $36.5M
Top Position Liquidated / Trimmed
BRKR
前期市值: $14.0M
In Q2 2025, Bellevue Group AG made 120 total portfolio adjustments, initiating 7 new buys, adding to 39 positions, trimming 61 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.